市场调查报告书
商品编码
1629880
全球给药设备市场 - 2025-2033Global Drug Delivery Devices Market - 2025-2033 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2023年,全球给药装置市场规模达857亿美元,预计2033年将达到1,365亿美元,2025-2033年预测期间复合年增长率为5.9%。
药物传输装置在现代医学中至关重要,它将药物化合物输送到特定的身体部位以获得所需的治疗效果。他们使用各种方法、配方和技术来优化药物给药、增强疗效并儘量减少副作用。传统方法可能会导致药物水平波动,进而影响治疗效果。新型药物输送系统 (NDDS) 提供控释机制,可长时间维持治疗药物浓度。
驱动程式和限制
科技进步的崛起
技术进步正在改变给药设备市场,提高给药效率和精确度。关键创新包括标靶药物传递系统,它将治疗药物引导至患病组织,最大限度地减少副作用并改善治疗结果,特别是在肿瘤学领域。口服给药技术也正在解决胃肠道降解和可变吸收率等挑战。
例如,植入式药物输送系统(IDDS)是一种治疗慢性病的新方法,提供受控和有针对性的治疗介入。与传统的口服药物不同,IDDS 可作为内部药物储存库,直接在作用部位或进入体循环提供精确的剂量。 IDDS 的一项有前景的应用是慢性疼痛管理,患者可以避免复杂的给药方案和与口服止痛药相关的潜在副作用。透过将镇痛剂直接输送到脑脊髓液中,IDDS 绕过血脑屏障,最大限度地减少全身暴露和副作用。可程式帮浦还可以控制药物释放,确保长时间持续缓解疼痛。
严格的监管要求
全球给药设备市场面临许多监管挑战,包括不同的地区要求、缺乏明确的指导方针以及日本等市场的严格监管。这可能会导致开发时间和成本增加,特别是对于整合药物和设备的组合产品。缺乏明确的指导方针可能会导致製造商在遵守特定标准方面感到困惑。
随着技术的发展,监管机构更加重视软体品质和网路安全,这增加了审批流程的复杂性。公司还必须做好准备,应对对製造品质和设备性能进行更严格的审查,这正成为全球监管机构的焦点。这些挑战需要製造商和监管机构之间进行策略规划和协作,以成功开发产品和进入市场。
The global drug delivery devices market reached US$ 85.7 billion in 2023 and is expected to reach US$ 136.50 billion by 2033, growing at a CAGR of 5.9% during the forecast period 2025-2033.
Drug delivery devices are crucial in modern medicine, transporting pharmaceutical compounds to specific body sites for desired therapeutic effects. They use various methods, formulations, and technologies to optimize drug administration, enhance efficacy, and minimize side effects. Traditional methods can cause fluctuations in drug levels, compromising treatment effectiveness. Novel Drug Delivery Systems (NDDS) provide controlled release mechanisms to maintain therapeutic drug concentrations over extended periods.
Market Dynamics: Drivers & Restraints
Rise in the Technological Advancements
Technological advancements are transforming the drug delivery devices market, improving medication administration efficiency and precision. Key innovations include targeted drug delivery systems, which direct therapeutic agents to diseased tissues, minimizing side effects and improving treatment outcomes, especially in oncology. Oral drug delivery technologies are also addressing challenges like gastrointestinal tract degradation and variable absorption rates.
For instance, Implantable drug delivery systems (IDDS) are a new approach to managing chronic conditions, offering a controlled and targeted therapeutic intervention. Unlike traditional oral medications, IDDS function as internal drug repositories, delivering precise doses directly at the site of action or into the systemic circulation. One promising application of IDDS is in chronic pain management, where patients can avoid complex dosing schedules and potential side effects associated with oral pain relievers. By delivering analgesic agents directly into the cerebrospinal fluid, IDDS bypasses the blood-brain barrier, minimizing systemic exposure and side effects. Programmable pumps also allow for controlled medication release, ensuring consistent pain relief for extended periods.
Stringent Regulatory Requirements
The global drug delivery devices market faces numerous regulatory challenges, including varying regional requirements, lack of clear guidelines, and stringent regulations in markets like Japan. This can lead to increased development times and costs, especially for combination products that integrate drugs and devices. The lack of clear guidelines can cause confusion among manufacturers regarding compliance with specific standards.
As technology evolves, regulators place greater emphasis on software quality and cybersecurity, adding complexity to the approval process. Companies must also be prepared for increasing scrutiny on manufacturing quality and device performance, which is becoming a focal point for regulatory bodies globally. These challenges require strategic planning and collaboration between manufacturers and regulators for successful product development and market entry.
The global drug delivery devices market is segmented based on device type, application, end user and region.
Injectable devices segment is expected to dominate the drug delivery devices market share
The injectable devices segment holds a major portion of the drug delivery devices market share and is expected to continue to hold a significant portion of the drug delivery devices market share during the forecast period.
Injectable devices are a key player in the global drug delivery market, driven by the increasing prevalence of chronic diseases like diabetes, cancer, and autoimmune disorders. These devices offer advantages like targeted administration, rapid absorption, and improved patient compliance. Technological advancements have led to the development of self-injectable devices and smart injectors, improving convenience and accuracy in medication delivery. The introduction of biologics and biosimilars further expands the market, as injectable systems provide precise dosing for these therapies. With rising healthcare expenditures, injectable devices are expected to become a cornerstone of modern therapeutic strategies.
For instance, in October 2024, UPM Biomedicals has launched FibGel, a natural injectable hydrogel for permanent implantable medical devices. Made from birch wood cellulose and water, FibGel is a safe, sustainable, and biocompatible alternative for medical device developers. Designed and manufactured under ISO 13485 standards in Finland, it is poised to transform soft tissue repair, orthopaedics, and regenerative medicine fields.
Cancer segment is the fastest-growing segment in drug delivery devices market share
The cancer segment is the fastest-growing segment in the drug delivery devices market share and is expected to hold the market share over the forecast period.
Cancer is driving the global drug delivery devices market, requiring advanced and targeted treatment methods. Innovative technologies like implantable pumps, transdermal patches, and nanoparticle-based carriers are being developed to improve therapeutic efficacy and minimize side effects. The integration of personalized medicine and immunotherapy in cancer care has accelerated advancements in devices delivering monoclonal antibodies, chemotherapy agents, and gene-editing solutions. These innovations aim to improve patient compliance, pharmacokinetics, and outcomes, bolstering the market's growth trajectory.
For instance, in November 2024, TriSalus Life Sciences Inc has launched the TriNav LV Infusion System and TriGuide Guiding Catheter, two advanced oncology innovations designed to optimize therapeutic delivery for liver and pancreatic tumor treatment, potentially improving patient outcomes and enhancing treatment options.
North America is expected to hold a significant position in the drug delivery devices market share
North America holds a substantial position in the drug delivery devices market and is expected to hold most of the market share due to the novel product launches, adoption of innovative medical technologies, and the prevalence of chronic diseases like diabetes and cancer. Regulatory support from organizations like the FDA encourages innovation and expedites the approval of advanced drug delivery systems. The presence of leading pharmaceutical and biotechnology companies and substantial R&D investments contribute to the development and commercialization of cutting-edge drug delivery solutions, making North America a major driver of growth.
For instance, in December 2024, NuGen Medical Devices has launched its InsuJet needle-free insulin delivery device in Canada, generating $670,000 in revenue. Launched on November 15, the device uses a simple spring-loaded mechanism to release the drug as a fine jet stream of liquid, allowing it to penetrate the skin through a microscopic entrance. The device dispenses the drug safely and evenly in less than one-tenth of a second, with minimal pain or skin damage. The device is approved for sale in 42 countries.
Europe is growing at the fastest pace in the drug delivery devices market
Europe holds the fastest pace in the drug delivery devices market and is expected to hold most of the market share due to the significant advancements, product launches, established healthcare system, patient-centric care, and rising prevalence of chronic diseases. The European Medicines Agency (EMA) and strong pharmaceutical and biotechnology industry, along with government initiatives to boost healthcare innovation, facilitate the development and approval of innovative drug delivery solutions. This combination, along with the rising prevalence of chronic diseases, contributes to Europe's pivotal role in the global drug delivery devices market.
For instance, in November 2024, Sol-Millennium Medical Group has launched the InsuJet Needle-free Device, a needle-free insulin administration device designed to improve the quality of life for Billions of diabetic patients by eliminating discomfort associated with traditional needle-based injections.
Moreover, in July 2024, Smithers opened a new laboratory near Frankfurt, Germany, focusing on testing medical devices and pharmaceutical products. The facility, part of the Smithers Medical Device Testing Division, will offer drug delivery device testing services to clients worldwide. The 800 square meters facility will be equipped with state-of-the-art equipment and is located 12 km from Frankfurt Airport, allowing for quicker transport of samples and regular client visits. The new facility will increase testing capabilities and capacity.
The major global players in the drug delivery devices market include Pfizer Inc, Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Sanofi, Boehringer Ingelheim, Merck & Co., Inc., Boston Scientific Corporation, Teva Pharmaceuticals Industries Ltd and among others.
Emerging Players
The emerging players in the drug delivery devices market include Portal Instruments, Eyenovia, Inc, Credence MedSystems and among others.
The global drug delivery devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
LIST NOT EXHAUSTIVE